Bio-Techne's stock price surged 5.04% during pre-market trading on Wednesday, following the release of its second-quarter fiscal 2026 financial results.

The life sciences company reported quarterly adjusted earnings of $0.46 per share, beating the analyst consensus estimate of $0.43 by 5.99 percent. This represents a 9.52 percent increase compared to the same period last year. Revenue for the quarter came in at $295.877 million, also surpassing the $290.191 million estimate by 1.96 percent.

The strong performance was driven by robust demand in key segments, including double-digit growth in its large pharma end-market for the fourth consecutive quarter. The company also noted improving performance in biotech and ongoing growth in the Asia-Pacific region, particularly China, for the third straight quarter. Additionally, Bio-Techne announced a quarterly dividend of $0.08 per share.